2020/07/01 by Yazeed Sawalha, David A. Bond, Lapo Alinari · 14 citations
Medicine · #Chronic Lymphocytic Leukemia Research #Lymphoma Diagnosis and Treatment #Viral-associated cancers and disorders #Ibrutinib #Medicine #Mantle cell lymphoma #Clinical trial #Oncology #Refractory (planetary science) #Lymphoma #Bruton's tyrosine kinase #Internal medicine #Chemotherapy #Cancer research #Leukemia #Chronic lymphocytic leukemia
paper · pdf · doi:10.2147/ott.s238832
published in OncoTargets and Therapy Volume 13, 6573-6581 (Dove Medical Press)
openalex publication_date 2020/07/01 · openalex created_date 2020/07/10 · openalex updated_date 2026/07/29
Mantle cell lymphoma (MCL) is an uncommon B-cell non-Hodgkin lymphoma characterized by an aggressive clinical course in the majority of patients. Despite recent improvements in outcomes, MCL remains incurable and a major therapeutic challenge. BTK inhibitors are the preferred treatment option for patients with relapsed/refractory MCL, including those unfit for chemotherapy or those with chemoresistant disease. In addition to ibrutinib and acalabrutinib, the FDA recently approved zanubrutinib for the treatment of patients with relapsed/refractory MCL based on the results of two Phase 2 clinical trials showing overall response rates of 85-87% with complete responses in 30-77% of patients. Compared with ibrutinib, zanubrutinib is more selective for BTK and has less off-target inhibition, which is thought to limit certain toxicities although direct comparative data are still lacking. This review article summarizes data from clinical trials of currently FDA-approved BTK inhibitors in MCL with a focus on zanubrutinib.